Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.
about
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseThe effects of ketamine and risperidone on eye movement control in healthy volunteers.Biomarkers for the effects of antipsychotic drugs in healthy volunteers.Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.Summary of information on human CYP enzymes: human P450 metabolism data.The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms.Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry.UPLC-Tandem Mass Spectrometry Method for Simultaneous Determination of Fluoxetine, Risperidone, and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Pharmacokinetics Study in Rats.An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescentsInteractions between the cytochrome P450 system and the second-generation antipsychotics.Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10Stereo-specific LC and LC-MS bioassays of antidepressants and psychotics.Metabolic drug interactions with new psychotropic agents.Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypesRelationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.The use of experimental design in the optimization of risperidone biodegradable nanoparticles: in vitro and in vivo study.Risperidone: a review.Developing in vitro-in vivo correlation of risperidone immediate release tablet.Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalentsBioequivalence and pharmacokinetic evaluation of two formulations of risperidone 2 mg : an open-label, single-dose, fasting, randomized-sequence, two-way crossover study in healthy male Chinese volunteersSafety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia.Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.Pharmacogenetics of clinical response to risperidone.Pharmacological risk factors for delirium after cardiac surgery: a review.Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms.Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone.Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review.Current approach to diagnosis and treatment of delirium after cardiac surgery.Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment.An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteersIn vitro-in vivo correlation of parenteral risperidone polymeric microspheres.Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions
P2860
Q28252209-23DA4A68-788B-4A2C-8820-7102B607D891Q30437913-CC140DF6-0DFC-4C89-874B-A5AE62F23732Q30498461-A4D7185E-D9B3-404D-B2C0-8593B6D12910Q30501297-7E7EBCBB-ACEB-4CC2-936D-4EE842B4258AQ31980098-1E513AAA-0C03-4527-90B4-8A1BA32340AEQ32103802-0B7F20EE-1E02-49EA-B434-9D2B4B91F073Q33254664-5A48EBF4-6456-443F-9B28-CB81243A71B7Q33421914-4ACB9413-C102-4A91-AC98-C272D0A6AA61Q33800810-E387B51A-9CBB-4356-B9C8-C0D397201CF5Q33921598-540BEE11-DCC3-49CD-A6DF-EB029A8F1FB8Q34188511-494BEF11-15EC-405A-9011-03981E8CF039Q34273450-86C83A43-E6F0-4AC7-A242-328E15709ECDQ34537662-F155234E-6FE0-4FC5-A1CE-3F98481F4800Q34612118-3D318356-A115-4D4B-8744-1C8E80F13E1CQ34831800-D05CDA78-2BDF-4503-989F-CFECC45F650EQ35096587-65AF1E56-77FE-4114-9D0C-E36786C4A083Q35287206-E9E24B9B-85B1-4834-9F3A-E869D62A1E2FQ35376254-8AEF56C1-827D-4C97-95C5-78F77394D9DBQ35619640-9A972755-BBD3-41E3-9712-1A11E92B6BACQ35826139-A1BF29C9-0EF1-44A7-A447-24C6B80C085DQ35847706-F48B318E-AE2D-44F8-8C97-7EE3553C7141Q35930139-1DCA921E-732C-43FC-B080-47388DDB1D89Q36150794-AC8B3A69-75D3-4C74-8E83-AACFBEC5EFC4Q36195102-C48E5086-7FBA-4385-821E-A2F35C51C265Q36235106-9541BC96-3097-4D92-BDC2-CF50709BF12AQ36767827-BD662051-B4F2-4B11-A743-79A1DC1D682AQ36873906-40E30243-313C-4BC6-85F0-CAA0E1195D63Q36969067-CE8CF1AF-6B77-42F6-95A2-2382D8B37298Q36984231-D47E5718-0F2D-48CD-9F68-07F4AED68C83Q38074712-4B9D31C8-FDD0-44E2-8A98-986B1C9F7D33Q38085505-E3505BDA-7125-4364-9365-6460CF28498FQ38086817-A64F8412-A721-465C-AA5E-9257D1A31C69Q38204833-AC512324-716C-469D-8B03-A631D66259A9Q38682742-F5DD5C43-BA3D-403C-AFB0-076403E40B4CQ38774790-1964B07B-FF04-46AB-A698-07F03D27C81DQ38799862-5587E69E-0F91-4429-945E-978ADB44A5C4Q39248594-7E8EC0A1-AE63-4329-97CD-44A049674BCCQ39837691-61BA672F-EDFD-4CF5-9EAA-5DD6A0E7844AQ40481751-B953069A-E58A-43D8-B1BD-48E6EEA0A59EQ41613849-F9E72844-2F6E-4948-8819-8C1F7C28692D
P2860
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Pharmacokinetics of the novel ...... response in healthy subjects.
@en
Pharmacokinetics of the novel ...... response in healthy subjects.
@nl
type
label
Pharmacokinetics of the novel ...... response in healthy subjects.
@en
Pharmacokinetics of the novel ...... response in healthy subjects.
@nl
prefLabel
Pharmacokinetics of the novel ...... response in healthy subjects.
@en
Pharmacokinetics of the novel ...... response in healthy subjects.
@nl
P2093
P356
P1476
Pharmacokinetics of the novel ...... response in healthy subjects.
@en
P2093
De Coster R
Heykants J
Jonkman JH
Van Peer A
Visscher HW
Woestenborghs R
P304
P356
10.1038/CLPT.1993.146
P407
P577
1993-09-01T00:00:00Z